


# **SAGE EVALUATION PROCESS**


Carsten Mantel and Stefano Malvoti

Geneva, 4 April 2019


# EVALUATION GOALS DEFINED AT START OF THE PROCESS



# EVALUATION UNFOLDED OVER A 12 MONTHS PERIOD



# A FIVE-STEP PROCESS ALLOWED TO CAPTURE INSIGHTS, PRIORITIZE AND IDENTIFY RECOMMENDATIONS




# TOPICS DISCUSSED AT SAGE MEETINGS, 2010-2017


Topic	# sessions	%	# for Decision	# for Discussion	# for Information
Vaccine-specific	68	40%	51 (75%)	14 (21%)	3 (4%)
Reports	54	32%	0 (0%)	7 (13%)	47 (87%)
Programmatic challenges	20	12%	5 (25%)	14 (70%)	1 (5%)
DoV / GVAP	12	7%	7	1	4
Financing	4	2%	0	4	0
Vaccine safety	4	2%	1	3	0
General policy	3	2%	0	3	0
Surveillance	2	1%	0	2	0
SAGE processes	2	1%	0	2	0
<b>TOTAL</b>	<b>169</b>		<b>64 (38%)</b>	<b>50 (30%)</b>	<b>55 (32%)</b>

# MORE THAN 100 RESPONDENTS PROVIDED FIRST VIEW ON AREAS FOR IMPROVEMENT

## Key Technical Partners Survey



## Stakeholders Survey



- Relationship with **RITAGs** / considering regional needs
- Relationship with **other WHO advisory bodies**
- **Meeting format and conduct**
- **Agenda setting** / topics selection

Key Technical  
Partners  
& Stakeholders


- **Working group** setup / access to external resources
- Process leading to **formulation of recommendations**
- **Dissemination** of recommendations / SAGE outputs
- Inclusion of **implementation needs**

Key Technical Partners only

- **Responsiveness** to emerging issues
- **Engagement in non-immunization matters**


Stakeholders  
only

# SURVEYS AND INTERVIEWS HIGHLIGHTED 14 AREAS DESERVING FURTHER DISCUSSION



- **Mission and scope**
- **SAGE in the next decade**
- **Research and development**
- **Other WHO Advisory Committees**
- **Work with regions and countries**
- **SAGE – RITAG – NITAG policy making chain**
- **Relations with global stakeholders**
- **Membership and chair selection**
- **Agenda setting**
- **Decision-making and Working Group processes**
- **Meetings setup and modus operandi**
- **Conflict of interest management**
- **Dissemination and communication of SAGE output**
- **Secretariat role and resources**

# A DIVERSE SAMPLE RESPONDED TO THE EVALUATION



\*Industry associations consolidated input \*\*BMGF, Gavi, UNICEF, US CDC



# ACTION LAB: FACILITATED ITERATIVE APPROACH MOVING BETWEEN BROADER POLICY DIMENSION AND TECHNICAL ASPECTS OF THE CHALLENGES

